The 10 references in paper R. Kazakov E., V. Evteev A., O. Muslimova V., I. Mazerkina A., E. Demchenkova Yu., E. Shikh V., Р. Казаков Е., В. Евтеев А., О. Муслимова В., И. Мазеркина А., Е. Демченкова Ю., Е. Ших В. (2018) “Перспективы использования полиморфизма C3435T гена P-гликопротеина ABCB1 в персонализированной медицине // Prospects of using C3435T polymorphism in the ABCB1 gene encoding P-glycoprotein in personalised medicine” / spz:neicon:vedomostincesmp:y:2017:i:4:p:212-220

1
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22(47): 7468–85.
(check this in PDF content)
2
Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the humanABCB1(MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13(8): 481–94.
(check this in PDF content)
3
Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in theMDR1(ABCB1) gene. J Pharmacol Exp Ther. 2004; 311(3): 1179–87.
(check this in PDF content)
4
Romanov BK. Regulation of myocardial lysosomal enzyme activity by calcium. Biomedical Chemistry 2005; 51(6): 634–42 (in Russian).
(check this in PDF content)
5
Li Y, Wang Y, Sun J, Li Y, Yang L. Distribution of the functionalMDR1 C3435T polymorphism in the Han population of China. Swiss Med Wkly. 2006; 136(23–24): 377–82.
(check this in PDF content)
6
Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T. Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneouslydown-regulatessteroidxenobioticreceptor mRNA. Biochem Biophys Res Commun. 2003; 306(1): 116–20.
(check this in PDF content)
7
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97(7): 3473–8.
(check this in PDF content)
8
Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence ofMDR1C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol. 2005; 60(2): 159–71.
(check this in PDF content)
9
Sychev DA, Ignatiev IV, Andreev DA, Poshukaeva LG, Kolkhir PV, Zhukova EE, et al. Glycoprotein P pharmacogenetic assessment role in digoxin pharmacotherapy individualization: a new approach for an old problem. Russian Journal of Cardiology 2006; (4): 64–8 (in Russian). al. The effect of 3435C>TMDR1gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol. 2006; 62(11): 933–7. 11. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al.MDR1gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002; 53(5): 526–34. 12. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, et al. A variant 2677A allele of theMDR1gene affects fexofenadine disposition. Clin P
(check this in PDF content)
10
Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, et 23. McBride BF, Yang T, Roden DM. Influence of the G2677T/C3435T haplotype ofMDR1on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J. 2009; 9(3): 194–201. 24. Sokova EA. Monitoring post-approvial drug safety in pregnancy:
(check this in PDF content)